Abstract
Pharmacological inhibition of monoamine reuptake transporters has been known for many years as an effective therapy to reduce food intake and body weight in obese subjects. However, most of the marketed drugs failed after a distinct period in clinical use and had to be withdrawn because of serious adverse effects resulting in a negative benefit–risk profile. The most common side effects for this drug class included increases in systemic or pulmonary blood pressure and/or heart rate, cardiac valvulopathies, higher cardiovascular event rates, psychiatric disorders, or high abuse potential. The recent withdrawal of sibutramine as result of its adverse actions on the cardiovascular system highlighted again the problems with this drug class in antiobesity therapy. Recent developments to combine reuptake inhibitors with other drug classes, for example, opioid antagonists seem to be a promising approach to improve the benefit–risk profile of these compounds.
This chapter will discuss the history of this drug class in appetite control, its mechanism of action, and the clinical effects of selected drugs from this class.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM (2008) Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 372:1906–1913
Axel AM, Mikkelsen JD, Hansen HH (2010) Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 35:1464–1476
Bello NT, Liang NC (2011) The use of serotonergic drugs to treat obesity – is there any hope? Drug Des Devel Ther 5:95–109
Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J (2002) Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 106:2459–2465
Bray GA, Greenway FL (1999) Current and potential drugs for treatment of obesity. Endocr Rev 20:805–875
Burcelin R, Uldry M, Foretz M, Perrin C, Dacosta A, Nenniger-Tosato M, Seydoux J, Cotecchia S, Thorens B (2004) Impaired glucose homeostasis in mice lacking the alpha1b-adrenergic receptor subtype. J Biol Chem 279:1108–1115
Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711
Clifford PS, Davis KW, Elliott AE, Wellman PJ (2007) Effects of ICV administration of the alpha1A-adrenoceptor antagonist 5-methylurapidil on concurrent measures of eating and locomotion after cocaine in the rat. Life Sci 81:1059–1065
Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581–588
Fishman AP (1999) Aminorex to fen/phen: an epidemic foretold. Circulation 99:156–161
Glick SD, Haskew RE, Maisonneuve IM, Carlson JN, Jerussi TP (2000) Enantioselective behavioral effects of sibutramine metabolites. Eur J Pharmacol 397:93–102
Goldman CK, Marino L, Leibowitz SF (1985) Postsynaptic alpha 2-noradrenergic receptors mediate feeding induced by paraventricular nucleus injection of norepinephrine and clonidine. Eur J Pharmacol 115:11–19
Greenway FL, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K, Cowley MA (2009a) Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 94:4898–4906
Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E (2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376:595–605
Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O’Neil P, Schumacher D, Smith D, Dunayevich E, Tollefson GD, Weber E, Cowley MA (2009b) Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 17:30–39
Greiser E (1973) Epidemiologic studies on the relation between use of appetite depressants and primary vascular pulmonary hypertension. Internist (Berl) 14:437–442
Hadler AJ (1967) Studies of aminorex, a new anorexigenic agent. J Clin Pharmacol J New Drugs 7:296–302
Haenisch B, Bonisch H (2011) Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther 129:352–368
Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A (1998) Thermogenic effects of sibutramine in humans. Am J Clin Nutr 68:1180–1186
Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AM, Raben A, Mikkelsen JD (2010) The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol 636:88–95
Hein L (2006) Adrenoceptors and signal transduction in neurons. Cell Tissue Res 326:541–551
Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ (1997) Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 121:1613–1618
James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363:905–917
Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM (2005) Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond) 29:509–516
Katsiki N, Hatzitolios AI, Mikhailidis DP (2011) Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘A new kid on the block’? Ann Med 43:249–258
Leibowitz SF (1970a) Hypothalamic beta-adrenergic “satiety” system antagonizes an alpha-adrenergic “hunger” system in the rat. Nature 226:963–964
Leibowitz SF (1970b) Reciprocal hunger-regulating circuits involving alpha- and beta-adrenergic receptors located, respectively, in the ventromedial and lateral hypothalamus. Proc Natl Acad Sci USA 67:1063–1070
Leibowitz SF, Brown O, Tretter JR, Kirschgessner A (1985) Norepinephrine, clonidine, and tricyclic antidepressants selectively stimulate carbohydrate ingestion through noradrenergic system of the paraventricular nucleus. Pharmacol Biochem Behav 23:541–550
Lesses MF, Myerson A (1994) Human autonomic pharmacology. XVI. Benzedrine sulfate as an aid in the treatment of obesity. 1938. Obes Res 2:286–292
Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142:532–546
Lucas JJ, Yamamoto A, Scearce-Levie K, Saudou F, Hen R (1998) Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. J Neurosci 18:5537–5544
Padwal RS, Majumdar SR (2007) Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369:71–77
Parsons AC, Shraim M, Inglis J, Aveyard P, Hajek P (2009) Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev: CD006219
Rothman RB, Baumann MH (2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95:73–88
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32–41
Rothman RB, Clark RD, Partilla JS, Baumann MH (2003) (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters. J Pharmacol Exp Ther 305:1191–1199
Rucker D, Padwal R, Li SK, Curioni C, Lau DC (2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335:1194–1199
Samanin R, Garattini S (1993) Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol 73:63–68
Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509–522
Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406–433
Terry P, Gilbert DB, Cooper SJ (1995) Dopamine receptor subtype agonists and feeding behavior. Obes Res 3(Suppl 4):515S–523S
Tsujii S, Bray GA (1992) Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists. Brain Res 587:226–232
Valentino MA, Lin JE, Waldman SA (2010) Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther 87:652–662
Vickers SP, Clifton PG, Dourish CT, Tecott LH (1999) Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl) 143:309–314
Weintraub M, Hasday JD, Mushlin AI, Lockwood DH (1984) A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 144:1143–1148
Wellman PJ, Davies BT, Morien A, McMahon L (1993) Modulation of feeding by hypothalamic paraventricular nucleus alpha 1- and alpha 2-adrenergic receptors. Life Sci 53:669–679
Wirth A, Krause J (2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286:1331–1339
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kintscher, U. (2012). Reuptake Inhibitors of Dopamine, Noradrenaline, and Serotonin. In: Joost, HG. (eds) Appetite Control. Handbook of Experimental Pharmacology, vol 209. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-24716-3_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-24716-3_15
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-24715-6
Online ISBN: 978-3-642-24716-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)